Reversible cardiac valve abnormalities with pergolide treatment;Valvulopathie réversible et traitement par pergolide

Revue Neurologique

Volumn 160, Issue 1, 2004, Pages 81-82

  Calomne, V ^a   Dupuis, M J M ^a   Muller, T ^a   Kempinere, F ^a  

^a Clinique Saint Pierre of Ottignies   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PERGOLIDE;

AORTA VALVE REGURGITATION; ARTICLE; CASE REPORT; HUMAN; MITRAL VALVE REGURGITATION; PARKINSONISM; PLEURAL FIBROSIS; PULMONARY HYPERTENSION; RETROPERITONEAL FIBROSIS; SYMPTOMATOLOGY; VALVULAR HEART DISEASE;

EID: 1542344863     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(04)70850-4     Document Type: Article

References (15)

1. AUSTIN SM, EL-HAYEK A, COMIANOS M, TAMULONIS DJ. (1993). Mitral valve disease associated with long-term ergotamine use. South Med J, 86: 1179-1181.
2. BOWLER JV, ORMEROD IE, LEGG NJ. (1986). Retroperitoneal fibrosis and bromocriptine. Lancet, 2: 446.
3. CONNOLLY HM, CRARY JL, MCGOON MD, HENSRUD DD, EDWARDS BS, EDWARDS WD, SCHAFF HV. (1997). Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med, 337: 581-588.
4. DANOFF SK, GRASSO ME, TERRY PB, FLYNN JA. (2001). Pleuropulmonary disease due to pergolide use for restless legs syndrome. Chest, 120: 313-316.
5. FLAHERTY KR, BATES JR. (1996). Mitral regurgitation caused by chronic ergotamine use. Am Heart J, 131: 603-606.
6. HARDY JC, CHEVALIER C, KAINS JP. (1991). Fibrose rétropé ritonéale: à propos de trois cas dont deux induits par la bromocriptine. Acta Urol Belgica, 59: 95-103.
7. HAUCK AJ, EDWARDS WD, DANIELSON GK, MULLANY CJ, BRESNAHAN DR. (1990). Mitral and aortic valve disease associated with ergotamine therapy for migraine. Arch Pathol Lab Med, 114: 62-64.
8. HERZOG A, MINNIE H, ZIEGLER R. (1989). Retroperitoneal fibrosis in a patient with macroprolactinoma treated with bromocriptine. BMJ, 2: 1315.
9. JIMENEZ-JIMENEZ FJ, LOPEZ-ALVAREZ J, SANCHEZ-CHAPADO M, et al. (1995). Retroperitoneal fibrosis in a patient with parkinson's disease treated with pergolide. Clin Neuropharmacol, 18: 277-279.
10. KAINS JPD, HARDY JC, CHEVALIER C, COLLIER A. (1990). Retroperitoneal fibrosis in two patients with parkinson's disease treated with bromocriptine. Acta Clin Belgica, 45: 306-310.
11. MONDAL BK, SURI S. (2000). Pergolide-induced retroperitoneal fibrosis. Int J Clin Pract, 54: 403.
12. MONTASTRUC JL, BAGHERI H, LAPEYRE-MESTRE M, SENARD JM. (1999). Pharmacovigilance et pharmacoépidémiologie: príncipes, définition, méthodes et actualités en neurologie. Rev Neurol (Paris), 155: 312-324.
13. PRITCHETT AM, MORRISON JF, EDWARDS WD, SCHAFF HV, CONNOLLY HM, ESPINOSA RE. (2002). Valvular heart disease in patient taking pergolide. Mayo Clin Proc, 77: 1280-1286.
14. REDFIELD MM, NiCHOLSON WJ, EDWARDS WD, TAJIK AJ. (1992). Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med, 117: 50-52.
15. SHAUNAK S, WILKINS A, PILLING JB, DICK DJ. (1999). Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. J Neurol Neurosurg Psychiatry, 66: 79-81.